DexTech Medical ABXSAT:DEX +2.91%32 Quick Ratio is 20.18 as of Mar. 2026, which is 18% below its 10-year median of 24.57. GuruFocus rates XSAT:DEX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, DexTech Medical AB ranks better than 92.42% on this metric.
DexTech Medical AB has a quick ratio of 20.18. It generally indicates good short-term financial strength.
The historical rank and industry rank for DexTech Medical AB's Quick Ratio or its related term are showing as below:
XSAT:DEX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.23 Med: 24.57 Max: 196.47
Current: 20.18
During the past 13 years, DexTech Medical AB's highest Quick Ratio was 196.47. The lowest was 0.23. And the median was 24.57.
XSAT:DEX's Quick Ratio is ranked better than 92.42% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs XSAT:DEX: 20.18
DexTech Medical AB (XSAT:DEX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
DexTech Medical AB Quick Ratio Related Terms
DexTech Medical AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for DexTech Medical AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:DEX vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, DexTech Medical AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexTech Medical AB Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DexTech Medical AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where DexTech Medical AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
DexTech Medical AB's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DexTech Medical AB (XSAT:DEX) has a Quick Ratio of 20.18 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on DexTech Medical AB and its competitors. This is 18% below median its historical median of 24.57. Over the past decade, DexTech Medical AB's Quick Ratio has ranged from 0.23 to 196.47. According to the industry distribution chart, DexTech Medical AB ranks #107 out of 1412 companies in the Biotechnology industry, placing it in the top 7.6%.
Is DexTech Medical AB's Quick Ratio too high?
DexTech Medical AB's current Quick Ratio of 20.18 is 18% below median its 10-year median of 24.57. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 196.47. The Biotechnology industry median Quick Ratio is 3.60. DexTech Medical AB's value of 20.18 is 460.6% above this industry median. Based on the distribution chart, DexTech Medical AB ranks #107 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, DexTech Medical AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DexTech Medical AB ranks #107 out of 1412 companies for Quick Ratio. This places DexTech Medical AB in the top 8% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. DexTech Medical AB's value of 20.18 is 460.6% above this benchmark. Historically, DexTech Medical AB's own Quick Ratio has ranged from 0.23 to 196.47 over the past decade. While the company's 10-year median is 24.57 vs. the industry median of 3.60, DexTech Medical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DexTech Medical AB's current Quick Ratio of 20.18 is 460.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on DexTech Medical AB and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexTech Medical AB's current Quick Ratio is 20.18, which is 18% below median its own 10-year median of 24.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current Quick Ratio of 20.18. The current Quick Ratio is 20.18, which is 18% below median its 10-year median of 24.57 and 460.6% above the Biotechnology industry median of 3.60. DexTech Medical AB's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current Quick Ratio is 20.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
32GF Score
Get the complete analysis for XSAT:DEX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:DEX has been successfully added to your 
